Severe cross-modal object recognition deficits in rats treated sub-chronically with nmda receptor antagonists are reversed by systemic nicotine: Implications for abnormal multisensory integration in schizophrenia

Neuropsychopharmacology

Volumn 37, Issue 10, 2012, Pages 2322-2331

  Jacklin, Derek L ^a   Goel, Amit ^b   Clementino, Kyle J ^a   Hall, Alexander W M ^a   Talpos, John C ^b   Winters, Boyer D ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Translational Research   (Belgium)

Author keywords

cross modal; ketamine; MK 801; spontaneous object recognition; tactile; visual

Indexed keywords

DIZOCILPINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE;

ABNORMAL MULTISENSORY INTEGRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS MODAL OBJECT RECOGNITION DEFICIT; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; INFORMATION PROCESSING; MALE; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; RAT; RECOGNITION; SCHIZOPHRENIA; TACTILE SPONTANEOUS OBJECT RECOGNITION; TASK PERFORMANCE; VISUAL SPONTANEOUS OBJECT RECOGNITION;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; KETAMINE; MALE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, LONG-EVANS; RECEPTORS, N-METHYL-D-ASPARTATE; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA;

EID: 84865235322     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.84     Document Type: Article

References (57)

1. Abdul-Monim Z, Neill JC, Reynolds GP (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 21: 198-205. (Pubitemid 46280471)
2. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982). Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17: 639-654. (Pubitemid 12090209)
3. Beninger RJ, Forsyth JK, Van Adel M, Reynolds JN, Boegman RJ, Jhamandas K (2009). Subchronic MK-801 behavioural deficits in rats: partial reversal by the novel nitrate GT 1061. Pharmacol Biochem Behav 91: 495-502.
4. Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J et al (2007). The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1- benzofuran-2- carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321: 716-725. (Pubitemid 46624485)
5. Braff DL (1989). Sensory input deficits and negative symptoms in schizophrenic patients. Am J Psychiatry 146: 1006-1011. (Pubitemid 19197977)
6. Brown AS (2011). Exposure to prenatal infection and risk of schizophrenia. Front Psychiatry 2: 63.
7. Butler PD, Silverstein SM, Dakin SC (2008). Visual perception and its impairment in schizophrenia. Biol Psychiatry 64: 40-47. (Pubitemid 351783245)
8. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28: 265-275.
9. de Gelder B, Vroomen J, Annen L, Masthof E, Hodiamont P (2003). Audio-visual integration in schizophrenia. Schizophr Res 59: 211-218. (Pubitemid 35284694)
10. de Gelder B, Vroomen J, de Jong SJ, Masthoff ED, Trompenaars FJ, Hodiamont P (2005). Multisensory integration of emotional faces and voices in schizophrenics. Schizophr Res 72: 195-203. (Pubitemid 39550990)
11. de Jong JJ, Hodiamont PP, Van den Stock J, de Gelder B (2009). Audiovisual emotion recognition in schizophrenia: reduced integration of facial and vocal affect. Schizophr Res 107: 286-293.
12. Enomoto T, Floresco SB (2009). Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure. Prog Neuropsychopharmacol Biol Psychiatry 33: 668-675.
13. Enomoto T, Noda Y, Mouri A, Shin EJ, Wang D, Murai R et al (2005). Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68: 1765-1774. (Pubitemid 41654359)
14. Ford JM, Gray M, Whitfield SL, Turken AU, Glover G, Faustman WO et al (2004). Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 61: 119-129. (Pubitemid 38146546)
15. Forwood SE, Winters BD, Bussey TJ (2005). Hippocampal lesions that abolish spatial maze performance spare object recognition memory at delays of up to 48 h. Hippocampus 15: 347-355. (Pubitemid 40668354)
16. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T et al (2011). NMDA receptors, cognition and schizophreniaFTesting the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62: 1401-1412.
17. Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT et al (2009). Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modeling" of schizophrenia. Psychopharmacology 205: 203-216.
18. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68. (Pubitemid 40139588)
19. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M et al (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63: 92-97. (Pubitemid 350234890)
20. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA et al (2009). TC-5619: an alpha7 neuronal nicotinic receptorselective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78: 803-812.
21. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA et al (2005). A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25: 4396-4405. (Pubitemid 40628784)
22. Itil T, Keskiner A, Kiremitci N, Holden JM (1967). Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 12: 209-212.
23. Jacobs GH, Fenwick JA, Williams GA (2001). Cone-based vision of rats for ultraviolet and visible lights. J Exp Biol 204(Part 14): 2439-2446. (Pubitemid 34869470)
24. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225. (Pubitemid 29067401)
25. Jones CK, Byun N, Bubser M (2012). Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37: 16-42.
26. Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG (2004). Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126: 591-598. (Pubitemid 38759253)
27. Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K et al (2000). Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol 393: 237-242. (Pubitemid 30193422)
28. Levin ED, McClernon FJ, Rezvani AH (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184: 523-539. (Pubitemid 43255869)
29. Lewis DA, Curley AA, Glausier JR, Volk DW (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35: 57-67.
30. Lewis DA, Gonzalez-Burgos G (2008). Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33: 141-165. (Pubitemid 350191315)
31. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959). Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81: 363-369.
32. Lyon L, Saksida LM, Bussey TJ (2011). Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. Psychopharmacology (Berl) 220: 647-672.
33. McGurk H, MacDonald J (1976). Hearing lips and seeing voices. Nature 264: 746-748.
34. Mouri A, Noda Y, Noda A, Nakamura T, Tokura T, Yura Y et al (2007). Involvement of a dysfunctional dopamine-D1/N-methyld- aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol 71: 1598-1609. (Pubitemid 47010913)
35. Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S et al (2012). GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62: 1574-1583.
36. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL et al (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128: 419-432.
37. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004). Identification of separable cognitive factors in schizophrenia. Schizophr Res 72: 29-39. (Pubitemid 39452903)
38. Pearl D, Yodashkin-Porat D, Katz N, Valevski A, Aizenberg D, Sigler M et al (2009). Differences in audiovisual integration, as measured by McGurk phenomenon, among adult and adolescent patients with schizophrenia and age-matched healthy control groups. Compr Psychiatry 50: 186-192.
39. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V et al (2007). SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32: 17-34. (Pubitemid 44967781)
40. Pratt JA, Winchester C, Egerton A, Cochran SM, Morris BJ (2008). Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 153(Suppl 1): S465-S470. (Pubitemid 351341020)
41. Reynolds GP, Abdul-Monim Z, Neill JC, Zhang ZJ (2004). Calcium binding protein markers of GABA deficits in schizophrenia- postmortem studies and animal models. Neurotox Res 6: 57-61.
42. Robertson HR, Feng G (2011). Annual Research Review: Transgenic mouse models of childhood-onset psychiatric disorders. J Child Psychol Psychiatry 52: 442-475.
43. Ross LA, Saint-Amour D, Leavitt VM, Molholm S, Javitt DC, Foxe JJ (2007). Impaired multisensory processing in schizophrenia: deficits in the visual enhancement of speech comprehension under noisy environmental conditions. Schizophr Res 97: 173-183. (Pubitemid 350088394)
44. Rushforth SL, Steckler T, Shoaib M (2011). Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology 36: 2774-2781.
45. Smith JW, Gastambide F, Gilmour G, Dix S, Foss J, Lloyd K et al (2011). A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl) 217: 255-269.
46. Stein BE, Meredith MA (1993). The merging of the senses. MIT Press: Cambridge M.A.
47. Stone DB, Urrea LJ, Aine CJ, Bustillo JR, Clark VP, Stephen JM (2011). Unisensory processing and multisensory integration in schizophrenia: a high-density electrical mapping study. Neuropsychologia 49: 3178-3187.
48. Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD (2009). alpha Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 56: 1001-1009.
49. Timmermann DB, Gronlien JH, Kohlhaas KL, Nielsen EO, Dam E, Jorgensen TD et al (2007). An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323: 294-307. (Pubitemid 47443280)
50. Timofeeva OA, Levin ED (2011). Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia. Neuroscience 195: 21-36.
51. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S et al (2011). RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336: 242-253.
52. Wildeboer KM, Stevens KE (2008). Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice. Brain Res 1224: 29-36.
53. Williams LE, Light GA, Braff DL, Ramachandran VS (2010). Reduced multisensory integration in patients with schizophrenia on a target detection task. Neuropsychologia 48: 3128-3136.
54. Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ (2004). Double dissociation between the effects of peripostrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci 24: 5901-5908. (Pubitemid 38859387)
55. Winters BD, Reid JM (2010). A distributed cortical representation underlies crossmodal object recognition in rats. J Neurosci 30: 6253-6261.
56. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK et al (2006). Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]- furo[2,3-c]pyridine-5- carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure- Factivity relationship. J Med Chem 49: 4425-4436. (Pubitemid 44036685)
57. Woodruff-Pak DS, Gould TJ (2002). Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev 1: 5-20.